Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Abstract Background Non-V600E BRAF mutated colorectal cancer (CRC) is a rare disease entity with specific clinical features. These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation. Notably, median overall survival...

Full description

Bibliographic Details
Main Authors: Eduard Callebout, Suzane Moura Ribeiro, Stephanie Laurent, Marc De Man, Liesbeth Ferdinande, Kathleen B. M. Claes, Joni Van der Meulen, Karen P. Geboes
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Cancer
Subjects:
Case report
Non-V600E BRAF mutation
Colon cancer
Regorafenib
Epithelial to mesenchymal transition
Online Access:http://link.springer.com/article/10.1186/s12885-019-5763-5

Internet

http://link.springer.com/article/10.1186/s12885-019-5763-5

Similar Items